Pharvaris N.V. PHVS 深 沪
等待开盘 06-03 09:30:00 美东时间
28.98
-0.120
-0.41%
华盛通- 最 高33.33
- 今 开28.95
- 成交量 32.37万股
- 最 低 28.33
- 昨 收 29.10
- 总市值 96.08万
- 52周最高 33.33
- 市盈率 静 --
- 换手率 976.50%
- 52周最低 16.00
- 委 比 -7.76%
- 总股本 3.32万
- 历史最高 42.86
- 量 比 1.49
- 振 幅 17.18%
- 历史最低 1.10
- 每 手 1
- 风险率 3.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share
All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the public offering price, less
05-08 18:03
Pharvaris shares are trading lower after the company reported worse-than-expected Q4 EPS results.
Pharvaris shares are trading lower after the company reported worse-than-expect...
04-02 20:09
Earnings Scheduled For April 2, 2026
Companies Reporting Before The Bell • Pharvaris (NASDAQ:PHVS) is estimated to r...
04-02 19:11
Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
Pharvaris presented positive data on deucrictibant for the prevention and treatment of bradykinin-mediated angioedema, highlighting its efficacy, safety, and potential to address unmet needs in HAE and AAE-C1INH.
2025-06-16 10:50
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Pharvaris announces new data on deucrictibant, showing its potential for single-dose durability, prophylactic/on-demand efficacy, and biomarker advancements in treating bradykinin-mediated angioedema.
2025-06-02 10:50
Oppenheimer Maintains Outperform on Pharvaris, Raises Price Target to $42
Oppenheimer analyst Justin Kim maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $38 to $42.
2024-09-06 20:14
Pharvaris Highlights Oral Treatment For Hereditary Angioedema Attacks, Data Presented At Bradykinin Symposium 2024
Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, is highlighting the differentiated
2024-09-05 18:51
